2018 American Transplant Congress
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry
1Duke University Medical Center, Durham, NC; 2CTI Consulting, Raleigh, NC.
Introduction:Belatacept (BEL) was FDA approved for Kidney Transplantation (KTx) June 2011. It has largely been evaluated in two controlled trials (N Engl J Med 2016;374:333-43).…2018 American Transplant Congress
Aggressive Immunosuppression Minimization Shortens BK Viremia, Does Not Improve Outcome, but Increases the Risk of De Novo Donor Specific Antibodies in Kidney Recipients
Background: Immunosuppression (IS) minimization is the gold-standard treatment of BK virus (BKV) viremia in kidney transplant recipients (KTRs). However, the optimal approach to IS reduction…2018 American Transplant Congress
Discard and Post-Transplant Outcomes Associated with Organs Donated after Drug-Overdose Death
The United States faces an overdose epidemic primarily affecting young adults who might represent a novel source of viable deceased-donor organs. Utilization and outcomes associated…2018 American Transplant Congress
The Utility of a CD31/CD68 Dual Immunohistochemical Stain to Improve Accurate Diagnosis of Antibody Mediated Rejection in Cardiac Transplantation
Thoracic Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
Antibody mediated rejection (AMR) occurs in 10%-20% of cardiac transplant patients and is associated with increased mortality. The endomyocardial biopsy, used to identify microvascular injury…2018 American Transplant Congress
CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients
Background: There is currently no means to predict late-onset CMV infection after a long course of post-transplant Valgancyclovir prophylaxis therapy and its development still negatively…2018 American Transplant Congress
Pharmacological Defatting of Steatotic Human Livers Using a Novel Perfusion Solution during Normothermic Machine Perfusion
Introduction: Steatosis is the leading reason for donor livers discarding and contributes significantly to the worsening shortage of organs for transplantation. Steatotic livers commonly fail…2018 American Transplant Congress
Clinical and Pathological Findings in Hepatitis C Positive Renal Transplant Recipients Following Alemtuzumab Induction
University of Maryland Medical Center, Baltimore.
BackgroundHistorically, renal transplant recipients (RTRs) with chronic hepatitis C (HCV) have worse long-term outcomes. Induction with alemtuzumab (ALM) in HCV positive RTRs has been postulated…2018 American Transplant Congress
Assessment and Outcomes of Medication Nonadherence in Pediatric Kidney Transplant Recipients: Results from the IMPACT Study
OBJECTIVE: Medication nonadherence (MNA) plays a key role in transplant (Tx) survival in pediatric kidney patients (pts). However, identification of MNA is challenging and tools…2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…2018 American Transplant Congress
Inflammation in Fibrotic Areas (i-IF/TA) Identifies a T Cell-Mediated Rejection Component of IF/TA with Poor Kidney Allograft Outcome
Paris Translational Research Center for Organ Transplantation, Paris, France.
Addressing the etiological heterogeneity of interstitial fibrosis in kidney allografts represents an important challenge to improve long-term transplant outcomes. We investigated the determinants, clinical and…
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 211
- Next Page »